Literature DB >> 21696849

[Efficacy assessment of Nutrilarm®, a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome].

C Creuzot-Garcher1, C Baudouin, M Labetoulle, P-J Pisella, F Mouriaux, A Meddeb-Ouertani, L El Matri, M Khairallah, F Brignole-Baudouin.   

Abstract

INTRODUCTION: Inflammation is one of the main mechanisms common to all forms of dry eye. Since polyunsaturated acids are known to show biological anti-inflammatory properties, the aim of this study was to evaluate the efficacy of dietary n-6 and n-3 fatty acids in patients suffering from ocular dryness. PATIENTS AND METHODS: One hundred and eighty-one patients diagnosed with bilateral moderate dry eye who were already treated with lachrymal substitutes were randomized in a double-blind international study to receive placebo or Nutrilarm(®) capsules (combination of omega-3 and omega-6), twice a day for 6 months. In all subjects, dryness feeling, overall subjective comfort, and ocular symptoms (burning, stinging, sandy and/or gritty sensation, light sensitivity, reflex tearing, and ocular fatigue) were evaluated at each visit. Furthermore, fluorescein tests (break-uptime and Oxford scheme) and lissamine green test were performed at each visit. The Schirmer test was performed at inclusion and after 6 months of treatment.
RESULTS: After 6 months of supplementation with Nutrilarm(®), both the BUT scores and ocular fatigue were significantly improved when compared with placebo (P=0.036 and P=0.044, respectively). There was a trend in favor of Nutrilarm(®) in terms of the efficacy evaluated by the investigator (P=0.061). Fewer patients experienced a feeling of severe dryness with Nutrilarm(®) compared with placebo after 6 months of treatment (2.5 and 9.3%, respectively), but the difference was not statistically significant.
CONCLUSION: Oral administration of a double supplementation dietary n-6 and n-3 fatty acids present an additional therapeutic advantage in patients suffering from ocular dryness who were already treated with lachrymal substitutes.
Copyright © 2011. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696849     DOI: 10.1016/j.jfo.2011.01.018

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  3 in total

1.  Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease.

Authors:  Laura E Downie; Sueko M Ng; Kristina B Lindsley; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2019-12-18

2.  A metabolomic approach to dry eye disorders. The role of oral supplements with antioxidants and omega 3 fatty acids.

Authors:  Carmen Galbis-Estrada; Maria Dolores Pinazo-Durán; Sebastián Martínez-Castillo; José M Morales; Daniel Monleón; Vicente Zanon-Moreno
Journal:  Mol Vis       Date:  2015-05-11       Impact factor: 2.367

Review 3.  Oxidative Stress in the Protection and Injury of the Lacrimal Gland and the Ocular Surface: are There Perspectives for Therapeutics?

Authors:  Camila Nunes Lemos; Lilian Eslaine Costa Mendes da Silva; Jacqueline Ferreira Faustino; Marina Zilio Fantucci; Adriana de Andrade Batista Murashima; Leidiane Adriano; Monica Alves; Eduardo Melani Rocha
Journal:  Front Cell Dev Biol       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.